Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

21.4%

3 terminated/withdrawn out of 14 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

64%

9 trials in Phase 3/4

Results Transparency

133%

8 of 6 completed trials have results

Key Signals

2 recruiting8 with results

Enrollment Performance

Analytics

Phase 4

5(41.7%)

Phase 3

4(33.3%)

Phase 2

3(25.0%)

12Total

Phase 4(5)

Phase 3(4)

Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (14)

Showing 14 of 14 trials

NCT05844982Phase 3Recruiting

Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy

Role: collaborator

NCT06539481Phase 4Recruiting

Open Label Trial Studying the Safety and Effectiveness of ILUVIEN® (190μg) in Children and Adolescents, Who Have Recurrent Non-infectious Uveitis Affecting the Posterior Segment of the Eye.

Role: lead

NCT05322070Phase 4Active Not Recruiting

Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis

Role: lead

NCT04469595Phase 4Active Not Recruiting

A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)

Role: lead

NCT02424019Phase 4Completed

Phase 4 IOP Signals Associated With ILUVIEN®

Role: lead

NCT01998412Unknown

Iluvien Registry Safety Study

Role: lead

NCT02472366Phase 4Completed

A Non-Randomized, Open-Label, Single Center Phase 4 Study of the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (Laser, Anti-VEGF) With or Without Intravitreal Corticosteroid Therapy

Role: lead

NCT02080091Terminated

Observational Study to Assess the Effect of Iluvien® in DME Patients Insufficiently Responsive to Available Therapies

Role: lead

NCT00695318Phase 2Terminated

Fluocinolone Acetonide Intravitreal Inserts in Geographic Atrophy

Role: lead

NCT00770770Phase 2Terminated

Fluocinolone Acetonide Intravitreal Inserts for Vein Occlusion in Retina

Role: lead

NCT01304706Phase 3Completed

Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study